Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.52 |
| ▸ | NPY1R | P25929 | 8/20 | 0.52 |
| ▸ | NPY2R | P49146 | 5/20 | 0.52 |
| ▸ | QRFPR | Q96P65 | 2/20 | 0.52 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.49 |
| ▸ | GNPAT | O15228 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5598748 | 1.00 | NPY4R (0.52) | NPY4RNPY5RNPY1RNPY2RQRFPR | |
| SCHEMBL4590047 | 0.99 | NPY4R (0.52) | NPY4RNPY5RNPY1RNPY2RQRFPR | |
| SCHEMBL2249230 | 0.99 | NPY4R (0.52) | NPY4RNPY5RNPY1RNPY2RQRFPR | |
| SCHEMBL30692729 | 0.96 | GNPAT (0.54) | NPY4RNPY5RNPY1RNPY2RQRFPR | |
| SCHEMBL29447211 | 0.96 | GNPAT (0.54) | NPY4RNPY5RNPY1RNPY2RQRFPR | |
| SCHEMBL30064048 | 0.94 | NPY4R (0.59) | NPY4RNPY5RNPY1RNPY2RQRFPR | |
| SCHEMBL31720889 | 0.93 | NPY4R (0.54) | NPY4RNPY5RNPY1RNPY2RQRFPR | |
| SCHEMBL30264635 | 0.93 | NPY4R (0.51) | NPY4RNPY5RNPY1RNPY2RQRFPR | |
| SCHEMBL30782711 | 0.92 | QRFPR (0.58) | NPY4RNPY5RNPY1RNPY2RQRFPR | |
| SCHEMBL31590213 | 0.92 | NPY4R (0.62) | NPY4RNPY5RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026040002-A1 | COMPOSITION AND METHOD FOR CARING FOR THE SKIN | L'OREAL (FR) | 2026-02-26 | — | — | WO | claimed |
| WO-2026040002-A1 | COMPOSITION AND METHOD FOR CARING FOR THE SKIN | L'OREAL (FR) | 2026-02-26 | — | — | WO | disclosed |
| US-11491212-B1 | Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B | CATALYST BIOSCIENCES, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| CN-113373128-B | Epoxide hydrolase mutant with improved catalytic efficiency and preparation method thereof | 深圳市微滴科技顾问有限公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-105112177-A | Antimicrobial foamable soaps | OHSO CLEAN INC | 2015-12-02 | — | — | CN | disclosed |
| US-7186687-B2 | Compositions and methods for treatment of Psoriasis | PROCYTE CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11491212-B1 | Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B | F13B, F13A1, F9 | NPY4R 556/4885NPY5R 647/4885NPY1R 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.